L-Glutamine

What it is

L-Glutamine is one of the 20 standard proteinogenic amino acids, classified by nutritional guidelines as conditionally essential — the body normally synthesises enough endogenously from glutamate via glutamine synthetase, but demand can exceed synthesis capacity in states of severe catabolic stress (sepsis, major trauma, burns >20 % total body surface area, gut-failure short-bowel syndrome, intensive endurance training), when plasma glutamine drops measurably below the normal range of ~500–900 µmol/L.

Functionally, glutamine is unusual among amino acids in the breadth of roles it occupies. It is the major nitrogen carrier in inter-organ amino-acid trafficking, shuttling nitrogen from skeletal muscle (the largest free-glutamine reservoir, holding roughly 60 % of the intramuscular free-amino-acid pool) to the liver, gut, kidney, and immune system. It is the principal metabolic fuel for enterocytes (intestinal epithelial cells) — ahead of glucose — and the preferred fuel for proliferating lymphocytes, neutrophils, and macrophages. It is a substrate for glutathione synthesis (γ-glutamyl-cysteinyl-glycine; glutamine contributes the γ-glutamyl carbon backbone via glutamate). It is a precursor for purine and pyrimidine nucleotide synthesis, making rapidly dividing cells particularly dependent on glutamine supply. And it is a precursor in the renal generation of ammonia used for acid-base buffering, contributing to the kidney's response to metabolic acidosis.

The "gut-barrier" framing that dominates UK consumer search derives from the enterocyte-fuel role. Enterocytes preferentially oxidise glutamine over glucose to generate ATP, supporting tight-junction protein expression (claudin-1, occludin, ZO-1), intestinal mucus production by goblet cells, and secretory IgA output by lamina propria plasma cells. The mechanism is well- characterised. Translation to clinical benefit in self-treated "leaky gut" presentations is much weaker — most existing trials are small, doses range widely, and "leaky gut" is not a recognised UK clinical diagnosis. NHS pathway for irritable bowel syndrome (the closest matching consumer presentation) is described in NICE CG61 and starts with dietary review, FODMAP advice, and GP work-up — not amino-acid supplementation.

Commercial L-glutamine is almost universally produced by bacterial fermentation. Corynebacterium glutamicum, isolated by Japanese researchers in 1957 and patented as a glutamate-producing strain (the original commercial source of MSG), is the dominant industrial organism. Modern production uses defined mineral-salt media with plant-derived carbohydrate substrate (sugar cane molasses, sugar beet, or corn-starch hydrolysate); the final crystalline L-glutamine product is pharmacopoeial-grade and contains essentially no animal-source material. UK-marketed glutamine in food supplements is vegan / vegetarian by default unless the capsule shell is gelatin (most clinical-grade products use HPMC vegan shell).

A pharmacokinetic note: oral L-glutamine is well absorbed via the apical sodium-dependent transporter ASCT2 in the small intestine. Peak plasma levels arrive 30–60 minutes after a typical supplement-tier dose, and plasma half-life is short (~1 hour) due to high tissue extraction by gut, liver, and immune tissue. This is one reason single 0.5–1 g supplement doses produce only transient plasma elevation — sustained tissue exposure requires repeated dosing or much higher single doses, which moves into clinical-nutrition trial-grade territory.

Camden's editorial position is that L-glutamine has a real and well-characterised biological role, a clear-but-limited evidence base in critical illness (REDOXS-tempered), an unconvincing sport-performance trial record at supplement-tier doses, and a mechanistically-attractive but trial-weak case for self-treated functional GI symptoms. UK consumers exploring it for "leaky gut" are better directed to the NHS IBS pathway first; supplemental L-glutamine is a reasonable optional adjunct once the underlying presentation has been evaluated.

How it works

Enterocytes — the absorptive cells of the small intestinal villus — use glutamine as their primary metabolic fuel, preferentially over glucose. Glutamine enters the enterocyte via the apical Na⁺-dependent ASCT2 transporter, is converted to glutamate by phosphate-dependent glutaminase, and feeds the TCA cycle via α-ketoglutarate. The ATP yield supports the energy- expensive functions of the epithelium: active nutrient transport, tight-junction maintenance (claudin-1, occludin, ZO-1 protein turnover), and goblet-cell mucin synthesis. Adequate glutamine supply during catabolic stress is hypothesised to preserve barrier integrity and reduce bacterial-translocation events — the mechanistic basis of clinical-nutrition glutamine supplementation in burns, sepsis, and post-surgical recovery.

Lymphocytes upregulate glutamine uptake during proliferation, driven by Myc-mediated transcriptional regulation of ASCT2 and glutaminase expression. Glutamine carbon enters anaplerotic TCA flux at α-ketoglutarate, supporting nucleotide synthesis for cell division and providing precursor for the non-essential amino acids needed in clonal expansion. The framing of glutamine as "immune-supportive" derives from this — though "immune support" is a UK regulatory non-claim, so labelling cannot use that language, only the descriptive "supports normal immune-cell metabolism" framing.

Glutathione synthesis depends on three amino acids: glutamate (derived from glutamine via glutaminase or from dietary glutamate), cysteine (rate-limiting in most cells; NAC is the cysteine-donor used pharmacologically), and glycine. Glutamine supplementation can raise intracellular glutamate availability and thereby support glutathione synthesis when cysteine is also sufficient. This is the mechanistic basis of pairing glutamine with NAC and glycine in glutathione-focused supplement stacks (see Camden's NAC and glutathione encyclopaedia entries for the upstream / downstream relationships).

Skeletal muscle releases glutamine into circulation during intense exercise — plasma glutamine can drop 10–30 % below baseline in prolonged endurance training. This led to the sport-nutrition framing of glutamine as recovery-supportive. In practice, supplement-tier doses (0.5–3 g) produce modest and transient plasma elevation; trial evidence for measurable performance, recovery, or overtraining-prevention benefit at these doses is weak and largely null. Clinical-nutrition doses in burns or trauma (20–30 g/day) sit in a different efficacy / safety regime and are not a self-treatment context.

A note on the REDOXS harm signal: the 2013 trial (Heyland et al., NEJM, PMID 23594003) randomised 1,223 critically ill mechanically ventilated adults with multi-organ failure to enteral and parenteral glutamine + antioxidants vs placebo. The glutamine arm showed a non-significant trend toward increased 28-day mortality and significantly worse hospital mortality. Proposed mechanism for harm includes glutamine-driven nitrogen load in failing kidneys, increased ammonia generation in failing livers, and possible feeding of glutamine-dependent inflammatory or tumour cells. UK and European critical-care guidelines now advise against high-dose parenteral glutamine in multi-organ failure. Food-supplement-tier doses (0.5–3 g/day) do not approach REDOXS dosing and the harm signal does not extend to that range in current evidence.